We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nevro Corp. (NVRO - Free Report) recently announced preliminary revenues for second-quarter 2021. The company expects to release detailed financial results for the period on Aug 4.
As per the preliminary report, second-quarter 2021 revenues are estimated to be $102.3 million, up by 81% from the year-ago quarter. The Zacks Consensus Estimate of $102.9 million remains above the preliminary figure.
The company, during its first-quarter 2021 earnings release in May, had guided second-quarter 2021 worldwide revenues in the band of $104-$106 million, reflecting growth of 84-88%.
Nevro expects its second-quarter 2021 U.S. revenues to be approximately $85 million, reflecting an uptick of 67% from the prior-year period. International revenues are expected to be around $17.3 million, indicating an improvement of 222% on a reported basis (up 191% at constant exchange rate) compared with the year-ago period.
Following this release on Jul 19, shares of the company were up 1% to close at $151.44 yesterday.
2021 Financial Outlook
On the back of continued pandemic-led uncertainties, Nevro plans to update its guidance for full-year 2021 when it reports full second-quarter financial results. Nonetheless, the company, during its first-quarter 2021 earnings release, had narrowed its financial outlook for the full-year 2021. It expected full-year 2021 revenues in the band of $440-$450 million, narrower than the previous range of $430-$450 million. This reflects an improvement of 22-24%. The Zacks Consensus Estimate for full-year revenues is currently pegged at $444.1 million.
The company’s expectation of mid-single-digit million revenue contribution in 2021 from Painful Diabetic Neuropathy treatment following its FDA approval of Senza System (which is specific to Nevro's 10 kHz stimulation) looks encouraging.
A Brief Q2 Analysis
Nevro has been observing a slower-than-expected recovery of procedural volumes in the overall pain market and specifically in the spinal cord stimulation market. This, in turn, has adversely impacted not only second-quarter revenues, but also resulted in lower trial procedures, which drove down revenues.
Meanwhile, the company’s preliminary projection of a robust improvement in revenues compared with the sequentially last-reported quarter, lifts our confidence.
Price Performance
Shares of the company have gained 13.1% in the past year compared with the industry’s 11.2% growth and the S&P 500's 31.6% rise.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Nevro carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Henry Schein, Inc. (HSIC - Free Report) , AMN Healthcare Services Inc (AMN - Free Report) and Align Technology, Inc. (ALGN - Free Report) .
Image: Bigstock
Nevro (NVRO) Reports Impressive Preliminary Q2 Revenues
Nevro Corp. (NVRO - Free Report) recently announced preliminary revenues for second-quarter 2021. The company expects to release detailed financial results for the period on Aug 4.
As per the preliminary report, second-quarter 2021 revenues are estimated to be $102.3 million, up by 81% from the year-ago quarter. The Zacks Consensus Estimate of $102.9 million remains above the preliminary figure.
The company, during its first-quarter 2021 earnings release in May, had guided second-quarter 2021 worldwide revenues in the band of $104-$106 million, reflecting growth of 84-88%.
Nevro expects its second-quarter 2021 U.S. revenues to be approximately $85 million, reflecting an uptick of 67% from the prior-year period. International revenues are expected to be around $17.3 million, indicating an improvement of 222% on a reported basis (up 191% at constant exchange rate) compared with the year-ago period.
Following this release on Jul 19, shares of the company were up 1% to close at $151.44 yesterday.
2021 Financial Outlook
On the back of continued pandemic-led uncertainties, Nevro plans to update its guidance for full-year 2021 when it reports full second-quarter financial results.
Nonetheless, the company, during its first-quarter 2021 earnings release, had narrowed its financial outlook for the full-year 2021. It expected full-year 2021 revenues in the band of $440-$450 million, narrower than the previous range of $430-$450 million. This reflects an improvement of 22-24%. The Zacks Consensus Estimate for full-year revenues is currently pegged at $444.1 million.
The company’s expectation of mid-single-digit million revenue contribution in 2021 from Painful Diabetic Neuropathy treatment following its FDA approval of Senza System (which is specific to Nevro's 10 kHz stimulation) looks encouraging.
A Brief Q2 Analysis
Nevro has been observing a slower-than-expected recovery of procedural volumes in the overall pain market and specifically in the spinal cord stimulation market. This, in turn, has adversely impacted not only second-quarter revenues, but also resulted in lower trial procedures, which drove down revenues.
Meanwhile, the company’s preliminary projection of a robust improvement in revenues compared with the sequentially last-reported quarter, lifts our confidence.
Price Performance
Shares of the company have gained 13.1% in the past year compared with the industry’s 11.2% growth and the S&P 500's 31.6% rise.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Nevro carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Henry Schein, Inc. (HSIC - Free Report) , AMN Healthcare Services Inc (AMN - Free Report) and Align Technology, Inc. (ALGN - Free Report) .
Henry Schein’s long-term earnings growth rate is estimated at 11.2%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare’s long-term earnings growth rate is estimated at 6.5%. It currently carries a Zacks Rank #2.
Align Technology’s long-term earnings growth rate is estimated at 23.2%. It currently carries a Zacks Rank #2.